RNA-targeted therapy
Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease
Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy